PUBMEDCENTRAL

April 9, 2010

Letter to Investigator

Dear Principal Investigator,

The following citations in your recent progress report/competing continuation application do not appear to be in compliance with the NIH Public Access Policy, and need to be addressed:

To bring your award into compliance, reply to all on to this email, and provide the PMCID after each paper listed above. Please note that the PMCID (the PubMed Central reference number, with a "PMC" prefix) is not the same as the PMID (the PubMed number).

If the paper has been published more than three months ago, only a PMCID can be used as evidence of compliance with the Policy. To obtain a PMCID, please review the submission instructions at http://publicaccess.nih.gov/submit_process.htm.

If the PMCID is not available for papers in press, or published within the last three months:

When using Submission Method A or B, indicate "PMC Journal - In Process" at the end of the full citation.

When using Submission Method C or D, provide a valid NIH Manuscript Submission System reference number (NIHMSID) at the end of the full citation.

If the paper does not fall under the Policy, please provide a brief explanation of why the manuscript is not covered by the Policy (see To what papers does the NIH Public Access Policy apply?).

Compliance with the NIH Public Access Policy is a legal requirement and a term and condition of all NIH awards. NIH awardees are responsible for ensuring that all steps of the NIHMS submission process are complete within three months of publication, and that evidence of compliance is included in all NIH applications, proposals and reports.

If you have any questions about the Policy, please check the NIH Public Access Website or send a note to PublicAccess@nih.gov.

Making published research funded by NIH accessible to everyone, including health care providers, patients, educators and scientists, helps advance science and improve human health. We all have a role to play in this goal, and we appreciate your efforts to make the NIH Public Access Policy successful.

U.S.Department of Health & Human Services

National Institutes of Health Public Access

The Public Access Policy ensures that the public has access to the published results of NIH funded research to help advance science and improve human health.

Home
1. Determine Applicability
2. Address Copyright
3. Submit Papers
4. Include PMCID in Citations
Policy Details
Info on Journals
Training/Communications
FAQ/Glossary
For Sponsored Programs
For NIH Employees
- For NIH Employee Authors
- For NIH Extramural Staff (NIH Access Only)

Contact Us

Overview

The NIH Public Access Policy ensures that the public has access to the published results of NIH funded research. It requires scientists to submit final peer-revie that arise from NIH funds to the digital archive PubMed Central *upon acceptance for publication*. To help advance science and improve human health, the Polic papers are accessible to the public on PubMed Central no later than 12 months after publication.

How to Comply

All of your papers that fall under the NIH Public Access Policy, whether in press or in print, must include evidence of compliance in all of your NIH applications a

1. **Determine Applicability**
   Does the NIH Public Access Policy apply to your paper?
2. **Address Copyright**
   Ensure your publishing agreement allows the paper to be posted to PubMed Central in accordance with the NIH Public Access Policy.
3. **Submit Paper**
   Submit papers to PubMed Central and approve public release.
4. **Include PMCID in Citations**
   Include the PMCID at the end of the full citation in your application or report.

Submission Methods

There are four methods to ensure that an applicable paper is submitted to PubMed Central (PMC) in compliance with the NIH Public Access Policy. Authors may use whichever method is most appropriate for them and consistent with their publishing agreement. Click on the method in the table for details.

	Method A Journal deposits final published articles in PubMed Central without author involvement	**Method B** Author asks publisher to deposit specific final published article in PMC	**Method C** Author deposits final peer-reviewed manuscript in PMC via the NIHMS	**Method D** Author completes submission of final peer-reviewed manuscript deposited by publisher in the NIHMS
Version of Paper Submitted	Final Published Article	Final Published Article	Final Peer-Reviewed Manuscript	Final Peer-Reviewed Manuscript
Task 1: Who starts the deposit process?	Publisher	Publisher	Author or designee, via NIHMS	Publisher
Task 2: Who approves paper for processing?	Publisher	Publisher	Author, via NIHMS	Author, via NIHMS
Task 3: Who approves paper for Pub Med Central display?	Publisher	Publisher	Author, via NIHMS	Author, via NIHMS
Participating journal/publisher	Method A Journals	Make arrangements with these publishers	Check publishing agreement	Check publishing agreement
Who is Responsible?	NIH Awardee	NIH Awardee	NIH Awardee	NIH Awardee
To cite papers, from acceptance for publication to 3 months post publication	PMCID or "PMC Journal- In Process"	PMCID or "PMC Journal- In Process"	PMCID or NIHMSID	PMCID or NIHMSID
To cite papers, 3 months post publication and beyond	PMCID	PMCID	PMCID	PMCID

Method A: Publish in a journal that deposits *all* final published articles in PubMed Central (PMC) without author involvement.

Some journals automatically deposit all NIH-funded final published articles in PubMed Central, to be made publicly available within 12 months of publication, without author involvement. See the list of these journals at http://publicaccess.nih.gov/submit_process_journals.htm#journals.

Method B: Make arrangements to have the publisher deposit a *specific* final published article in PubMed Central.

Some publishers will deposit an individual final published article in PubMed Central upon author request, and generally for a fee. See the list of publishers at

Reply all

- Program Officer
- Sponsored Research Office
- NIA eRA Notifications
  ageranotifications@mail.nih.gov

Publication List

*PubMed Central embargoed publications will link to PubMed and display the PMC availability date between parentheses.

Pub Date	Source Identifier *(embargoed until)	PA Compliance	Pub Title	Journal (Impact)	Pub Authors
2010 Apr 5	PMID19908235 - -	Questionable Compliance	Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers.	American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics	Adams, P E; Adams, J S; Nguyen, D V; H Brunberg, J A; Tassone, F; Zhang, W; Ko K; Rivera, S M; Grigsby, J; Zhang, L; Dec Hagerman, P J; Hagerman, R J
2010 Jan 19	PMID20042704 PMCID2809036 -	PA Compliant	Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.	Neurology	Petersen, R C; Aisen, P S; Beckett, L A; D M C; Gamst, A C; Harvey, D J; Jack Jr, C Jagust, W J; Shaw, L M; Toga, A W; Troja Q; Weiner, M W
2009 Dec 15	PMID20007524 PMCID2790222 -	PA Compliant	Association of parental dementia with cognitive and brain MRI measures in middle-aged adults.	Neurology (7.043)	Debette, S; Wolf, P A; Beiser, A; Au, R; Hi Pikula, A; Auerbach, S; Decarli, C; Sesha
2009 Dec	PMID19726595 PMCID2777470 -	PA Compliant	Metabolic evidence of vitamin B-12 deficiency, including high homocysteine and methylmalonic acid and low holotranscobalamin, is more pronounced in older adults with elevated plasma folate.	The American journal of clinical nutrition (6.74)	Miller, Joshua W; Garrod, Marjorie G; Alle Lindsay H; Haan, Mary N; Green, Ralph
2009 Nov	PMID19901172 - -	Questionable Compliance	Differences in brain volume, hippocampal volume, cerebrovascular risk factors, and apolipoprotein E4 among mild cognitive impairment subtypes.	Archives of neurology	He, Jing; Farias, Sarah; Martinez, Oliver; Bruce; Mungas, Dan; Decarli, Charles
2009 Nov 24	PMID19846830 PMCID2788808 -	PA Compliant	Regional pattern of white matter microstructural changes in normal aging, MCI, and AD.	Neurology (7.043)	Lee, D Y; Fletcher, E; Martinez, O; Ortega Zozulya, N; Kim, J; Tran, J; Buonocore, M Carmichael, O; DeCarli, C
2009 Sep	PMID19752306 - -	Questionable Compliance	Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts.	Archives of neurology	Farias, Sarah Tomaszewski; Mungas, D Bruce R; Harvey, Danielle; DeCarli, Char
2009 Jun	PMID19403891 PMCID2774231 NIHMS136203	PA Compliant	Do tests of executive functioning predict ability to downregulate emotions spontaneously and when instructed to suppress?	Cognitive, affective & behavioral neuroscience (3.132)	Gyurak, Anett; Goodkind, Madeleine S; M Anita; Kramer, Joel H; Miller, Bruce L; Le Robert W
	PMID19437501				Xie, Jing; Alcantara, Dan; Amenta, Nina;

Results: 1 to 20 of 27

The emotional brain: combining insights from patients and basic science.

1. Rosen HJ, Levenson RW.
Neurocase. 2009 Jun;15(3):173-81.
PMID: 20183547 [PubMed - in process]
Related articles

Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions.

2. Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Grossman P, van Swieten JC, Murrell JR, Ghetti B, Spina S, Grafman J, Hodges J, Spillantini MG, Gilman S, Lieberman AP, Kaye JA, Woltjer RL, Bigio EH, Me Ferrer I, Lladó A, Neumann M, Kretzschmar HA, Hulette CM, Welsh-Bohmer KA, Miller BL, Alzualde A, de Munain AL, McKee AC, Gearing M, Levey Feldman HH, Hamilton RL, Dekosky ST, van der Zee J, Kumar-Singh S, Van Broeckhoven C, Mayeux R, Vonsattel JP, Troncoso JC, Kril JJ, Kwok J McLean CA, DeCarli C, Ellis WG, Freeman SH, Frosch MP, Growdon JH, Perl DP, Sano M, Bennett DA, Schneider JA, Beach TG, Reiman EM, Wo I, Hartikainen P, Seilhean D, Galasko D, Masliah E, Cotman CW, Tuñón MT, Martínez MC, Munoz DG, Carroll SL, Marson D, Riederer PF, Bogdan VM.
Nat Genet. 2010 Mar;42(3):234-9. Epub 2010 Feb 14.
PMID: 20154673 [PubMed - in process]
Related articles

Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals.

3. Hua X, Lee S, Hibar DP, Yanovsky I, Leow AD, Toga AW, Jack CR Jr, Bernstein MA, Reiman EM, Harvey DJ, Kornak J, Schuff N, Alexander GE, W Initiative.
Neuroimage. 2010 May 15;51(1):63-75. Epub 2010 Feb 6.
PMID: 20139010 [PubMed - in process]
Related articles

Nat Genet. 2010 Mar;42(3):234-9. Epub 2010 Feb 14.

Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions.

Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Grossman M, Arnold SE, Mann DM, Pickering-Brown SM, Seelaar H, Heutink P, van Swieten JC, Murrell JR, Ghetti B, Spina S, Grafman J, Hodges J, Spillantini MG, Gilman S, Lieberman AP, Kaye JA, Woltjer RL, Bigio EH, Mesulam M, Al-Sarraj S, Troakes C, Rosenberg RN, White CL 3rd, Ferrer I, Lladó A, Neumann M, Kretzschmar HA, Hulette CM, Welsh-Bohmer KA, Miller BL, Alzualde A, de Munain AL, McKee AC, Gearing M, Levey AI, Lah JJ, Hardy J, Rohrer JD, Lashley T, Mackenzie IR, Feldman HH, Hamilton RL, Dekosky ST, van der Zee J, Kumar-Singh S, Van Broeckhoven C, Mayeux R, Vonsattel JP, Troncoso JC, Kril JJ, Kwok JB, Halliday GM, Bird TD, Ince PG, Shaw PJ, Cairns NJ, Morris JC, McLean CA, DeCarli C, Ellis WG, Freeman SH, Frosch MP, Growdon JH, Perl DP, Sano M, Bennett DA, Schneider JA, Beach TG, Reiman EM, Woodruff BK, Cummings J, Vinters HV, Miller CA, Chui HC, Alafuzoff I, Hartikainen P, Seilhean D, Galasko D, Masliah E, Cotman CW, Tuñón MT, Martínez MC, Munoz DG, Carroll SL, Marson D, Riederer PF, Bogdanovic N, Schellenberg GD, Hakonarson H, Trojanowski JQ, Lee VM.

[1] Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. [2] These authors contributed equally to this work.

Frontotemporal lobar degeneration (FTLD) is the second most common cause of presenile dementia. The predominant neuropathology is FTLD with TAR DNA-binding protein (TDP-43) inclusions (FTLD-TDP). FTLD-TDP is frequently familial, resulting from mutations in GRN (which encodes progranulin). We assembled an international collaboration to identify susceptibility loci for FTLD-TDP through a genome-wide association study of 515 individuals with FTLD-TDP. We found that FTLD-TDP associates with multiple SNPs mapping to a single linkage disequilibrium block on 7p21 that contains TMEM106B. Three SNPs retained genome-wide significance following Bonferroni correction (top SNP rs1990622, P = 1.08 x 10(-11); odds ratio, minor allele (C) 0.61, 95% CI 0.53-0.71). The association replicated in 89 FTLD-TDP cases (rs1990622; P = 2 x 10(-4)). TMEM106B variants may confer risk of FTLD-TDP by increasing TMEM106B expression. TMEM106B variants also contribute to genetic risk for FTLD-TDP in individuals with mutations in GRN. Our data implicate variants in TMEM106B as a strong risk factor for FTLD-TDP, suggesting an underlying pathogenic mechanism.

PMID: 20154673 [PubMed - in process]

PMCID: PMC2828525 [Available on 2010/9/1]

Am J Med Genet B Neuropsychiatr Genet. 2010 Apr 5;153B(3):775-85.

Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers.

Adams PE, Adams JS, Nguyen DV, Hessl D, Brunberg JA, Tassone F, Zhang W, Koldewyn K, Rivera SM, Grigsby J, Zhang L, Decarli C, Hagerman PJ, Hagerman RJ.

M.I.N.D. Institute, University of California, Davis Health System, Sacramento, California, USA.

Fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder occurring in male and occasional female carriers of a premutation expansion (55-200 CGG repeats) of the fragile X mental retardation 1 gene assessed the relationship between hippocampal volume and psychological symptoms in carriers, both with and without FXTAS, and controls. Volumetric MRI measures, clinical staging, cognitive testing, molecular analysis, and r psychological symptoms were performed for female premutation carriers both with FXTAS (n = 16, age: 57.50 + or - 12.46) and without FXTAS (n = 17, age: 44.94 + or - 11.23), in genetically normal female controls (n = 8, age: 50.6 carriers with FXTAS (n = 34, age: 66.44 + or - 6.77) and without FXTAS (n = 21, age: 52.38 + or - 12.11), and genetically normal male controls (n = 30, age: 57.20 + or - 14.12). We examined the relationship between psychological s hippocampal volume, as well as correlations with molecular data. We found a significant negative correlation between total hippocampal volume and anxiety in female carriers, with and without FXTAS. This finding was mainly drive negative correlation between right hippocampal volume and anxiety. Other anxiety-related subscales also correlated with the right hippocampus in females. In male carriers with and without FXTAS, only paranoid ideation negativel hippocampal volume. Female premutation carriers demonstrated a negative association between hippocampal volume and the severity of anxiety-related psychological symptoms. Though the presentation of FXTAS symptoms is females, anxiety-related problems are common both prior to and after the onset of FXTAS, and may be related to hippocampal changes.

PMID: 19908235 [PubMed - in process]